CD274 and gastric cancer: In the KEYNOTE-059 phase II study, patients with PD-L1 positive (CPS ≥ 1%) gastric cancer had a higher ORR of 15.5% than patients with PD-L1 negative (CPS < 1%) gastric cancer, with an ORR of 6.4% when treated with pembrolizumab as \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\ge$$\end{document}≥ 3rd-line therapy [7].